» Articles » PMID: 39404874

Macrophage Activation Syndrome in Sepsis: from Pathogenesis to Clinical Management

Overview
Journal Inflamm Res
Date 2024 Oct 15
PMID 39404874
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Sepsis represents a significant global health and hygiene challenge. Excessive activation of macrophages in sepsis can result in certain patients displaying characteristics akin to those observed in Macrophage Activation Syndrome (MAS). MAS represents a grave immune system disorder characterized by persistent and severe inflammation within the body. In the context of sepsis, MAS presents atypically, leading some researchers to refer to it as Macrophage Activation-Like Syndrome (MALS). However, there are currently no effective treatment measures for this situation. The purpose of this article is to explore potential treatment methods for sepsis-associated MALS.

Objective: The objective of this review is to synthesize the specific pathophysiological mechanisms and treatment strategies of MAS to investigate potential therapeutic approaches for sepsis-associated MALS.

Method: We searched major databases (including PubMed, Web of Science, and Google Scholar etc.) for literature encompassing macrophage activation syndrome and sepsis up to Mar 2024 and combined with studies found in the reference lists of the included studies.

Conclusion: We have synthesized the underlying pathophysiological mechanism of MALS in sepsis, and then summarized the diagnostic criteria and the effects of various treatment modalities utilized in patients with MAS or MALS. In both scenarios, heterogeneous treatment responses resulting from identical treatment approaches were observed. The determination of whether the patient is genuinely experiencing MALS significantly impacts the ultimate outcomes of therapeutic efficacy. In order to tackle this concern, additional clinical trials and research endeavors are imperative.

Citing Articles

Fostamatinib, a Spleen Tyrosine Kinase Inhibitor, Exerts Anti-Inflammatory Activity via Inhibiting STAT1/3 Signaling Pathways.

Guo R, Liao H, Meng Y, Shi X, He Y, Zhu Z J Inflamm Res. 2024; 17:9757-9771.

PMID: 39618932 PMC: 11606345. DOI: 10.2147/JIR.S486753.

References
1.
Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

2.
Rudd K, Johnson S, Agesa K, Shackelford K, Tsoi D, Kievlan D . Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020; 395(10219):200-211. PMC: 6970225. DOI: 10.1016/S0140-6736(19)32989-7. View

3.
Chiu C, Legrand M . Epidemiology of sepsis and septic shock. Curr Opin Anaesthesiol. 2021; 34(2):71-76. DOI: 10.1097/ACO.0000000000000958. View

4.
Yao Y, Deng H, Li P, Zhang J, Zhang J, Wang D . α-Lactose Improves the Survival of Septic Mice by Blockade of TIM-3 Signaling to Prevent NKT Cell Apoptosis and Attenuate Cytokine Storm. Shock. 2016; 47(3):337-345. DOI: 10.1097/SHK.0000000000000717. View

5.
Delano M, Ward P . The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016; 274(1):330-353. PMC: 5111634. DOI: 10.1111/imr.12499. View